Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective

Marie Johne1,2 | Kerstin Römermann1 | Philip Hampel1,2 | Björn Gailus1,2 | Wiebke Theilmann1 | Tommi Ala-Kurikka3 | Kai Kaila | Wolfgang Löscher1,2

1Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany
2Center for Systems Neuroscience, Hannover, Germany
3Molecular and Integrative Biosciences and Neuroscience Center (HiLIFE), University of Helsinki, Helsinki, Finland

Correspondence
Wolfgang Löscher, Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Bünteweg 17, D-30559 Hannover, Germany.
Email: wolfgang.loescher@tiho-hannover.de

Funding information
Deutsche Forschungsgemeinschaft, Grant/ Award Number: Lo 274/15-1

Abstract
Objective: Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia. Phenobarbital is currently the most widely used antiseizure drug for treatment of neonatal seizures, but fails to stop them in ~50% of cases. In a neonatal hypoxia-only model based on 11-day-old (P11) rats, the NKCC1 inhibitor bumetanide was reported to potentiate the antiseizure activity of phenobarbital, whereas it was ineffective in a human trial in neonates. The aim of this study was to evaluate the effect of clinically relevant doses of bumetanide as add-on to phenobarbital on neonatal seizures in a noninvasive model of birth asphyxia in P11 rats, designed for better translation to the human term neonate.

Methods: Intermittent asphyxia was induced for 30 minutes by exposing the rat pups to three 7 + 3–minute cycles of 9% and 5% O2 at constant 20% CO2. Drug treatments were administered intraperitoneally either before or immediately after asphyxia.

Results: All untreated rat pups had seizures within 10 minutes after termination of asphyxia. Phenobarbital significantly blocked seizures when applied before asphyxia at 30 mg/kg but not 15 mg/kg. Administration of phenobarbital after asphyxia was ineffective, whereas midazolam (0.3 or 1 mg/kg) exerted significant antiseizure effects when administered before or after asphyxia. In general, focal seizures were more resistant to treatment than generalized convulsive seizures. Bumetanide (0.3 mg/kg) alone or in combination with phenobarbital (15 or 30 mg/kg) exerted no significant effect on seizure occurrence.

Significance: The data demonstrate that bumetanide does not increase the efficacy of phenobarbital in a model of birth asphyxia, which is consistent with the negative data of the recent human trial. The translational data obtained with the novel rat model of birth asphyxia indicate that it is a useful tool to evaluate novel treatments for neonatal seizures.

KEYWORDS
antiseizure drugs, GABA, neonates, NKCC1
Neonatal seizures are the most common neurological emergency in the neonatal period, occurring in 1-5 per 1000 live births. Prolonged perinatal asphyxia is a major cause of seizures and hypoxic-ischemic encephalopathy in the neonatal population. Notwithstanding its potential toxicity in neonates, the antiseizure drug (ASD) phenobarbital is still the first-line therapy. However, despite the use of high doses of phenobarbital (10-40 mg/kg), seizures are controlled in fewer than one-half of the neonates. Variable efficacy (ranging from minimal to 100%) has been reported for the benzodiazepine, midazolam, as a second-line medication. Neonates with continued seizures have a poor prognosis, including significant mortality and, in survivors, serious sequelae such as mental retardation, a wide range of neuropsychiatric disorders, motor deficits, and epilepsy. Thus, improving the treatment of neonatal seizures is an urgent medical need.

Phenobarbital potentiates the effect of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) by enhancing the hyperpolarizing chloride (Cl⁻) ion-mediated current across GABA<sub>A</sub> receptors in target neurons. The transmembrane electrochemical Cl⁻ gradient of neurons is set by the interaction of Cl⁻-permeable channels and by secondary-active ion-transporters, of which the Cl⁻ importer NKCC1 and the Cl⁻ exporter KCC2 are the major ones. Several studies have shown that KCC2 expression in the human neonate is high, which results in the low intracellular Cl⁻ concentration required for the hyperpolarizing action of GABA. However, following neuronal trauma, downregulation KCC2 and up-regulation of NKCC1 may occur. As a result, Cl⁻ inbound transport exceeds the outbound transport, so that intracellular Cl⁻ levels are high, thus resulting in a reversed Cl⁻ gradient. This results in a change in the functionality of GABA in damaged neurons, which becomes depolarizing/excitatory rather than hyperpolarizing/inhibitory, possibly explaining the poor efficacy of phenobarbital and other ASDs (eg, benzodiazepines such as midazolam) that act via GABAergic mechanisms in neonates. However, whether and to what extent this mechanistic scheme is valid for the brain of the asphyxiated human neonate is not known.

Based on preclinical studies, the potent loop diuretic, bumetanide, has been proposed to be useful in suppressing seizures following perinatal brain injury, because it may restore GABAergic inhibition by blocking neuronal NKCC1 in the brain, thereby increasing the efficiency of phenobarbital and other positive modulators of GABA<sub>A</sub> receptors to suppress neonatal seizures. This prompted two clinical trials in newborn babies with seizures to examine the efficacy of bumetanide, administered together with phenobarbital (US Food and Drug Administration Investigational New Drug No. 101690: http://clinicaltrials.gov/ct2/show/NCT00830531; EU FP7 NEMO: http://www.nemo-europe.com/). The European trial with bumetanide (0.05-0.3 mg/kg) as adjunct to phenobarbital (10 mg/kg) for treatment of neonatal seizures was stopped early because of serious adverse reactions (ototoxicity) and no evidence for seizure reduction. The US trial was started in 2009, but the results have not been published as yet.

The negative outcome of the European trial raises questions about the translational value of the preclinical models that have been used to evaluate the effect of bumetanide and phenobarbital combinations. For instance, in the study of Cleary et al., 10-day-old (P10) rat pups were exposed to hypoxia for 15 minutes, which induced acute seizures in 95% of vehicle controls during the hypoxia. When phenobarbital (15 mg/kg intraperitoneal [ip]) and/or bumetanide (0.15 or 0.3 mg/kg ip) were administered prior to seizure induction, phenobarbital or bumetanide alone did not significantly reduce seizure incidence, whereas a reduction by 75%-85% was obtained by combining either dose of bumetanide with phenobarbital. The authors concluded that “these data provide preclinical support for clinical trials of bumetanide in human neonates at risk for hypoxic encephalopathy and seizures.” However, in human asphyxiated neonates, seizures occur mainly during the recovery period following perinatal asphyxia, not during the hypoxic episode associated with complicated birth. Asphyxia is, by definition, a combination of hypoxia and hypercapnia, and recent work has shown the elevation in brain CO<sub>2</sub> levels has robust brain-sparing effects, whereas the recovery to normocapnia (and the associated rise in pH) promotes seizures in the model used in the present study.
The aim of this study was to evaluate whether the anti-seizure effect of bumetanide/phenobarbital combinations reported by Cleary et al. for a rat hypoxia-only model of neonatal seizures is also observed in a novel asphyxia model of such seizures. For this goal, we used a model of birth asphyxia recently described by us in P11-12 rats, which correspond to term human babies. In contrast to hypoxia-only models such as the one used by Cleary et al., seizures in this asphyxia model develop after the insult, which closely parallels the situation in human neonates. For characterizing the pharmacology of the asphyxia-induced seizures in rat pups, we administered phenobarbital and the potent benzodiazepine, midazolam, either before or after the period of asphyxia. Furthermore, we tested bumetanide alone and in combination with phenobarbital, using the doses and administration schedule described in the study of Cleary et al.

2 | MATERIALS AND METHODS

2.1 | Animals

Breeding pairs of Wistar Han (Crl:WI[Han] outbred) rats were obtained from Charles River. The animals were kept under controlled environmental conditions (22-24°C; 50%-60% humidity; 12-hour light/dark cycle; light on at 6:00 AM) with free access to standard laboratory chow (Altromin 1324 standard diet; Altromin) and tap water. Male and female offspring were used at P11 (where P0 refers to the day of birth). Each litter was separated into pups that served as controls and pups that were used for drug treatment as described below. The numbers of breeder pairs and litters used for the present study are shown in Table S1.

Experiments were performed in Hannover, Germany, according to the EU council directive 2010/63/EU and the German Law on Animal Protection (Tierschutzgesetz). Ethical approval for the study was granted by an ethical committee (according to §15 of the Tierschutzgesetz) and the governmental agency (Lower Saxony State Office for Consumer Protection and Food Safety) responsible for approval of animal experiments in Lower Saxony (reference number for this project: 17/2604). All efforts were made to minimize both the suffering and the number of animals. A total of 173 rat pups were used for the present experiments. All animal experiments of this study are reported in accordance with ARRIVE guidelines.

2.2 | Asphyxia model of neonatal seizures

Details of this novel model are reported elsewhere. For the present experiments, the intermittent asphyxia protocol was slightly modified, because the previously used protocol with alternating 5-minute periods of 9% O2/20% CO2 and 5% O2/20% CO2 with a total duration of 30 minutes was associated with high mortality in the present experiments, most likely attributable to subtle substrain differences in the Wistar outbred rats used in the present and previous work (cited above). The protocol illustrated in Figure 1 was used. In short, the rat pups were placed in exposure chambers (one per chamber), with a constant temperature of 35.5°C, 15 min prior to exposure to asphyxia; under these conditions the animals’ rectal temperature stabilizes to 36-37 °C. Intermittent asphyxia was induced for 30 minutes by exposing the rat pups to three cycles of 7 minutes 9% O2 and 3 minutes 5% O2 at a constant elevated level of CO2 (20% of atmospheric pressure), as illustrated in Figure 1. Gases were humified and delivered at a flow rate of 3000 mL/min into two exposure chambers; the size of each chamber was 12 x 12.2 x 12.3 cm, resulting in a chamber volume of 1800 cm³. When possible, control and drug-treated pups were performed in parallel, using one chamber per animal. After the asphyxia protocol, animals were promptly re-exposed to room air. Animals were closely observed during and for at least 10 minutes after asphyxia by two investigators, who were blinded to the treatments. Furthermore, the animals’ behavior was video-monitored by two cameras, one from the side and one from above, to allow offline post hoc analyses of behavioral alterations. In the absence of drug treatment, all animals developed seizures within 10 minutes after the end of asphyxia (see Results). The type and severity of these seizures were scored by a modified Racine scale as described in Table 1. Furthermore, paroxysmal behavioral symptoms and automatisms that could not be rated by this scale were noted. Mortality associated with asphyxia was recorded. For sham asphyxia, all experimental procedures were identical, except that the pups were exposed to room air in the chambers used for asphyxia.

In some experiments, the cortical electroencephalogram (EEG) was recorded before, during and after asphyxia. Epidural EEG screw electrodes were implanted into the skull above the motor cortex 1 day before asphyxia under anesthesia with isoflurane. Stereotactic coordinates for the cortical electrode in millimeters from bregma were anteroposterior (AP), +1.5; mediolateral (ML), +1.5. A reference screw electrode was implanted at AP, +1.5; ML, −1.5; and a grounding screw at AP, −3.8; ML, +2.0. The EEG was recorded in freely moving rat pups with simultaneous video recording, using the parameters and EEG/video equipment described in detail previously.

2.3 | Drug treatment

As shown in Figure 1, three drugs were evaluated: phenobarbital (15 or 30 mg/kg ip), midazolam (0.3 or 1 mg/kg
and bumetanide (0.3 mg/kg ip). The latter drug was administered either alone or in combination with phenobarbital (15 mg/kg or 30 mg/kg ip). Doses of phenobarbital and bumetanide were those used by Cleary et al.14 These doses are in the range used clinically in human neonates.3 In experiments, in which phenobarbital and bumetanide were administered before asphyxia, we used the pretreatment times described by Cleary et al as illustrated in Figure 1. Midazolam was injected immediately before or after asphyxia. Furthermore, in an additional experiment, phenobarbital (30 mg/kg ip) was injected 15 minutes before or immediately after asphyxia. Because phenobarbital (30 mg/kg) was not effective when administered immediately after asphyxia (see Results), we examined whether bumetanide (0.3 mg/kg) administered together with phenobarbital (30 mg/kg) after asphyxia increases the efficacy of phenobarbital. Together with each drug experiment, a group of untreated rat pups was tested in parallel in a treatment-blind manner. Rat pups were randomly assigned to the different groups. For midazolam, which was dissolved in sterile water for injection, concurrent controls received the vehicle. This also allowed evaluating whether vehicle injection induced any differences compared to untreated controls. Maternal separation was equally long in test and control animals.

2.4 | Drug analysis in plasma and brain

Some drug-treated animals were killed 10 minutes after asphyxia (after the seizure surveillance period) for determining drug concentrations in plasma and brain. Phenobarbital, bumetanide, and midazolam were extracted from plasma and brain and determined by high-performance liquid chromatography with ultraviolet detection as described previously.23,24 Detection limit for bumetanide in the brain tissue was 0.009 µg/g.

2.5 | Drugs

Phenobarbital (used as sodium salt; Serva) was dissolved in sterile water. For experiments in which bumetanide (Sigma) was administered before asphyxia, it was dissolved in a
| Seizure stage | Behavioral symptoms | Alterations in cortical EEG | Comments | Clinical correlates in neonates |
|---------------|---------------------|-----------------------------|----------|--------------------------------|
| I             | Mouth or facial clonus | No change observed | Nonconvulsive (limbic?) | Oral-buccal automatism (e.g., mouthing, chewing) |
|               | Head nodding/ shaking and/or ≥ 2 myoclonic twitches of whole body (rapid isolated jerks) | No change observed | Nonconvulsive (limbic?) | Epileptic spasms (may result in head nodding and/or rapid isolated myoclonic jerks (random single contractions) |
| III           | Uni- or bilateral repetitive clonic seizures of limbs (without loss of righting) | Epileptic activity (see Figure 2) | Generalized convulsive (motor) | Clonic seizures (repetitive jerking, unifocal or multifocal); seizure type best recognized clinically |
| IV            | Uni- or bilateral repetitive clonic seizures of limbs and tonic seizures of fore- or hindlimbs (without loss of righting) | Epileptic activity (see Figure 2) | Generalized convulsive (motor); rearing (as in the original Racine scale) is not observed in the rat pups | Clonic seizures (repetitive jerking, unifocal or multifocal) |
| V             | Repetitive clonic seizures of limbs and tonic seizures of fore- or hindlimbs (± wild running) with loss of righting (falling) | Epileptic activity (see Figure 2) | Generalized convulsive (motor) | Tonic stiffening; decerebrate posturing; usually focal, unilateral or bilateral asymmetric; sustained posturing of limb/trunk |
| Other paroxysmal symptoms (not rated) | Backing; Straub tail; limb posturing and movements (e.g., swimming, pedaling); flexion or bending of body or limbs resembling infantile spasms | No change observed | | Subtle seizures are the most common seizure type in both preterm and term babies; manifestations include ocular phenomena (staring, blinking, eye deviation, eye opening), oral phenomena (see stage I), fragmentary body movements (limb posturing, swimming, pedaling), autonomic phenomena |
| Stereotyped behaviors (not rated) | Grooming, circling, wet-dog shakes | No change observed | May occur before, in-between, or after seizures; not clear whether these behaviors represent nonconvulsive limbic seizures | Motor automatisms |

Note: For clinically obvious seizures, seizure type and severity were graded by a modified Racine scale. The different seizure stages do not have to occur in sequence (from lowest to highest stage), but, presumably because of involvement of different brain structures, may occur in a mixed manner. Seizures originating presumably from the limbic system (e.g., mouth clonus, stereotypies) are likely to occur before seizures originating from forebrain cortical areas (e.g., clonic) or the brain stem (tonic seizures). None of the clinically obvious seizures or other paroxysmal behavioral symptoms shown in the table occurred after sham asphyxia (see text). For the clinically obvious seizures and other paroxysmal behavioral symptoms occurring after asphyxia in rat pups, clinical correlates in neonates are shown for comparison (based on the current International League Against Epilepsy classification recently reported by Pressler et al). Abbreviation: EEG, electroencephalogram.
vehicle containing 5% ethanol, 5% Solutol HS 15 (a nonionic solubilizer consisting of ethoxylated 12-hydroxystearic acid; BASF), and 90% distilled water. For experiments in which bumetanide was administered together with phenobarbital after asphyxia, we dissolved this drug together with phenobarbital in an aqueous 10% solution of hydroxypropyl-β-cyclodextrin (HPβCD; Kleptose, Roquette-Pharma), which contained 2.25% glucose. Preliminary experiments did not indicate any differences in drug pharmacokinetics, including brain distribution. The reason for avoiding the ethanol/Solutol solution shortly after asphyxia was the potential antiseizure activity of ethanol administered shortly before onset of seizures.23 Midazolam was used as commercial aqueous solution of its hydrochloride (midazolam-hameln), which was diluted by sterile water. All drugs were injected ip; injection volume was 10 mL/kg, except for combined treatment with bumetanide and phenobarbital before asphyxia, for which injection volume was 3 mL/kg per drug, and treatment with midazolam, for which injection volume was 1.7 mL/kg.

2.6 | Statistics

In all experiments, rat pups from a given litter were randomly assigned to the drug and vehicle groups and experiments were performed in a blinded fashion. Statistical analyses were performed using GraphPad Prism 8.0 software. Either parametric or nonparametric tests were used for statistical evaluation, depending on data distribution. For comparison of two groups, either Student t test, Mann-Whitney U test, or Wilcoxon signed rank test was used, depending on whether data were paired. In case of more than two groups, we used analysis of variance (ANOVA) with post hoc testing and correction for multiple comparisons. Depending on data distribution, either the ANOVA F test, followed post hoc by Dunnett multiple comparisons test, or the Kruskal-Wallis test followed post hoc by Dunn multiple comparisons test was used. For comparison of frequencies in a 2 × 2 table, Barnard unconditional test25 was used, because this test preserves the significance level and generally is more powerful than Fisher exact test for moderate to small samples.26 All tests were used two-sided; P < .05 was considered significant. G*Power Data Analysis27 was used to calculate the necessary sample size for a specified power of 80%.

3 | RESULTS

3.1 | Behavioral alterations during and after asphyxia in P11 rats

Exposing the rat pups to the asphyxia protocol shown in Figure 1 did not produce any obvious behavioral effects, apart from brief agitation on initiation of the exposure. Seizures were never seen during the asphyxia. However, following establishment of normocapnic conditions after asphyxia, all rat pups exhibited clinically obvious seizures (stage I-V) within 0.5-7.4 minutes (mean = 2.1 minutes). These seizures occurred repeatedly over a period of 0.5-8.97 minutes (mean = 3.7 minutes) postasphyxia, after which the animals resumed normal behavior. In agreement with previous findings16 and as shown in Table 2, the predominant seizure type was generalized convulsive (stage III-V) seizures, particularly generalized tonic-clonic (stage V) seizures. The average latency to convulsive stage III-V seizures was 2.2 minutes (range = 1.0-3.88 minutes). Individual group values for seizure latencies are shown in Table S2. Representative examples of seizures are shown in Video S1.

In addition, several other paroxysmal symptoms, which were not observed following sham asphyxia, were determined in the pups, including fragmentary body movements (limb posturing, swimming, pedaling) that are also seen following asphyxia in human neonates (Table 1; Video S1). Similarly, stereotyped behaviors, described as motor automatisms during human neonatal seizures, were determined in the rat pups (Table 1; Video S1). When these other paroxysmal symptoms and automatisms were included in calculation of latency to first symptom after termination of asphyxia, a latency period of 0.33-3.5 minutes (mean = 1.31 minutes) was obtained. In this respect, it is important to note that subtle seizures are the most common seizure type in both preterm and term babies, with manifestations such as ocular phenomena (staring, blinking, eye deviation, eye opening), oral phenomena, fragmentary body movements (limb posturing, swimming, pedaling), and autonomic phenomena.1 In the rat pups of the present asphyxia model, distinct types of such subtle seizures were observed in 30%–60% of the animals (Table 2).

Again, in agreement with previous work,16 the typical generalized convulsive (stage III-V) seizures recorded after asphyxia were paralleled by paroxysmal, epileptic activity in the cortical EEG (Table 1). Examples of such EEG alterations are illustrated in Figure 2B-D. The clinical seizures observed during EEG recording are illustrated above each EEG trace. In apparent contrast to generalized convulsive stage III-V seizures, stage I/II limbic seizures and the other paroxysmal symptoms and automatisms observed in the rat pups after asphyxia were not paralleled by cortical EEG alterations (Table 1), indicating that they arose from subcortical or paleocortical areas such as the limbic system. During asphyxia, the EEG amplitude was suppressed compared to the preasphyxia baseline (Figure 2A).

The average number of clinically obvious (stage I-V) seizures following termination of asphyxia was 2.44 (range = 1-5) per animal. Seizures typically progressed through several stages (see examples in Figure 2). Average seizure severity (using the highest rated seizure per animal) was 3.83 (range = 1-5).
| Clinically obvious seizures and other paroxysmal behavioral symptoms and stereotypes after asphyxia in P11 rats | Treatment before asphyxia | Treatment after asphyxia |
|-------------------------------------------------|---------------------------|--------------------------|
| Untreated, all        | Vehicle, all              | Untreated, all           | Vehicle, all              |
| Number of pups tested |                           |                          |                          |
| No seizures           | 0/23                      | 0/28                     | 1/17                     | 2/10                     | 4/5                      | 1/9                      | 0/13                     | 5/15 (P = .0041)          | 10/19 (P = .00015) |
| Nonconvulsive seizures (focal; I-III)            | 8/23                      | 1/28                     | 2/8                      | 2/8                      | 7/17                     | 4/10                     | 1/5                      | 2/9                      | 1/13                     | 10/15 (P < .0001)       | 4/19                     |
| Convulsive seizures (III-V)                       | 15/23                     | 27/28                    | 2/8                      | 0/8 (P = .011)           | 9/17                     | 4/10                     | 0/5 (P = .0002)           | 6/9                      | 12/13                    | 0/15 (P < .0001)       | 5/19                     |
| Total [I-V]                                             | 23/23                     | 28/28                    | 4/8 (P = .0041)          | 2/8 (P = .00012)         | 16/17                    | 8/10                     | 1/5 (P = .0018)           | 8/9                      | 13/13                    | 10/15 (P = .0041)      | 9/19 (P = .00015)       |
| Average seizure severity, score ± SEM              | 3.83 ± 0.32               | 4.5 ± 0.17               | 1.25 ± 0.49              | 0.38 ± 0.26              | 3.18 ± 0.41              | 2.2 ± 0.47 (P < .0001)   | 0.2 ± 0.2 (P < .0001)   | 3.22 ± 0.68              | 4.77 ± 0.22              | 1.9 ± 0.09 (P < .0001) | 1.53 ± 0.47 (P < .0001) |
| Other paroxysmal symptoms [see Table 1]           | 8/23                      | 13/28                    | 3/8                      | 0/8 (P = .049)           | 7/17                     | 3/10                     | 0/5                      | 4/9                      | 2/13                     | 0/15 (P = .0016)       | 5/19 (P = .026)        |
| Stereotypies [see Table 1]                         | 7/23                      | 15/28                    | 1/8                      | 1/8                      | 7/17                     | 5/10                     | 0/5                      | 1/9                      | 11/13 (P = .0018)       | 5/15 (P = .00064)      | 2/19 (P = .00064)      |
| Total [seizures and other paroxysmal symptoms or stereotypes] | 23/23                     | 28/28                    | 5/8 (P = .039)           | 2/8 (P = .00012)         | 16/17                    | 10/10                    | 1/5 (P = .0018)           | 8/9                      | 13/13                    | 10/15 (P = .0041)      | 9/19 (P = .00015)      |
| Mortality                                             | 4/27                      | 0/28                     | 0/8                      | 1/9                      | 9/26                     | 1/11                     | 1/6                      | 2/11                     | 0/13                     | 2/15 (P = .00015)      | 0/19                     |

Note: Drug treatment was either performed before asphyxia or immediately after asphyxia as shown in Figure 1. Significant differences from either untreated animals or, for midazolam, from a concurrent vehicle group are shown. Total incidence of seizures or other paroxysmal symptoms in untreated animals did not significantly differ from those observed in the vehicle group. P values of significant differences between drug-treated groups and controls are indicated. No sex differences were observed in any group (see text).

Abbreviation: P11, postnatal day 11.
When data were calculated separately for male (n = 14) and female pups (n = 9), no significant differences in average latency to first seizure (1.5 ± 0.2 minutes vs 1.8 ± 0.4; P = .4662), the average period over which seizures were observed (3.8 ± 0.7 minutes vs 3.0 ± 0.7 minutes; P = .4504), and the average number of seizures (2.7 ± 0.3 vs 2.9 ± 0.4 seizures/pup; P = .6888) were obtained. Furthermore, as shown in Figure S1, all untreated controls and all vehicle-injected controls of both sexes exhibited 100% seizure incidence.

Rat pups that were injected with vehicle (sterile water) before or after asphyxia appeared to exhibit more convulsive (stage III-V) seizures than untreated controls (Table 2; Figure 3). This, however, was a random effect that was not observed when analyzing additional groups of untreated P11 rat pups (data not shown).

Mortality associated with asphyxia was low (Table 2) and not affected by litter size. Rat pups typically died during the last 5 minutes of asphyxia. The surviving rat pups exhibited no obvious alterations in body weight gain or general health status in subsequent weeks (not illustrated).

In view of the relatively short latencies between the end of asphyxia and onset of seizures, which is a potential problem for drug efficacy testing when drugs are administered after asphyxia (see below), we evaluated several modifications of the protocol illustrated in Figure 1. When the duration of intermittent asphyxia was increased from 30 minutes to 40 or 60 minutes, the average latency to convulsive seizures increased by only ~10% but mortality largely increased to 30% and 50%, respectively. We therefore decided to use the protocol illustrated in Figure 1 for drug experiments.
Treatment with 15 mg/kg phenobarbital 15 minutes before onset of asphyxia did not significantly reduce postasphyxic seizure incidence when compared to a concurrent untreated control group (Figure 3A). However, when compared to all untreated controls used in this study, a significant (50%) decrease in clinically obvious (stage I-V) seizures and a 38% decrease in all seizures were observed in the phenobarbital-treated pups (Table 2). When the dose of phenobarbital was increased to 30 mg/kg, a significant 75% decrease in seizure incidence was obtained (Figure 3A, Table 2). The generalized convulsive (stage III-V) seizures were completely prevented by this dose, whereas nonconvulsive stage I-II seizures were resistant to treatment.

Bumetanide 0.3 mg/kg administered alone 15 minutes before onset of asphyxia did not significantly reduce seizures.
of any stage developing after asphyxia (Figure 3B; Table 2). Furthermore, a combination of phenobarbital (15 mg/kg; 30 minutes before asphyxia) and bumetanide (0.3 mg/kg; 15 minutes before asphyxia) did not exert any significant effect on seizures of any stage. Instead, combination with bumetanide tended to decrease the antiseizure efficacy of phenobarbital compared to treatment with phenobarbital alone ($P = .071$). Furthermore, in the group treated with bumetanide alone, 35% of the pups died compared to 15% in untreated controls, which, however, was not significant ($P = .1187$).

Obviously, ASDs can be administered to the neonate in the neonatal intensive care unit only after parturition when recovery from asphyxia starts, not during or before. Therefore, we performed experiments in which drugs were injected immediately after the termination of asphyxia (Figure 1). With phenobarbital 30 mg/kg, no significant antiseizure effect was observed. This can be explained by the short latent period (about 2 minutes; see above) between termination of asphyxia and onset of postasphyxic seizures, because phenobarbital penetrates into the brain and cerebrospinal fluid
relatively slowly.\textsuperscript{28,29} When bumetanide (0.3 mg/kg) was injected together with phenobarbital (30 mg/kg) shortly after asphyxia, again no significant antiseizure effect was determined (Figure 3B); however, the incidence of stereotypies was increased significantly (Table 2).

In contrast, midazolam (1 mg/kg) potently suppressed seizures when administered before or after asphyxia (Table 2; Figure 3C). When administered before asphyxia, the antiseizure effect of midazolam was similar to that of high-dose phenobarbital in that a significant 80% decrease in seizure incidence was observed. Again, the generalized convulsive (stage III-V) seizures were completely prevented by this dose of midazolam, whereas nonconvulsive stage I-II seizures were resistant to treatment. When midazolam (1 mg/kg) was injected after asphyxia, seizure incidence was reduced by 53%. Benzodiazepines are known to penetrate into the brain within seconds after parental injection,\textsuperscript{30} thus explaining the beneficial efficacy compared to phenobarbital when injected after asphyxia in our model.

Based on the significant antiseizure effect of midazolam (1 mg/kg) injected after asphyxia, we performed an additional experiment in which we decreased the dosage of midazolam to 0.3 mg/kg. As shown in Table 2 and Figure 3C, midazolam significantly reduced the incidence of seizures by 33%, thus demonstrating that the effect of midazolam was dose-dependent. However, the generalized convulsive (stage III-V) seizures were completely prevented by this dose of midazolam, whereas nonconvulsive stage I-II seizures were resistant to treatment.

In none of the drug experiments were obvious differences between male and female pups observed (Figure S1). At the lower dose of phenobarbital, male rat pups appeared to be more responsive to the anticonvulsant effect of this drug than female pups; however, the low sample size per sex excluded any meaningful quantification. Only for the experiments with the higher dose of midazolam (1 mg/kg) after asphyxia was group size per sex large enough for determining potential sex differences. The number of midazolam responders was similar in male (6/9) and female (5/10) rat pups in this experiment (Figure S1C).

In addition to determining the effects of drugs on seizure incidence, we also evaluated whether drug treatment exerted an effect on seizure latency. As shown in Table S2, except for midazolam (1 mg/kg after asphyxia), none of the treatments significantly altered the latency to seizure onset after asphyxia. Midazolam increased the latency to nonconvulsive seizures 2.4-fold compared to seizure latency determined after injection of the midazolam vehicle.

All drug experiments described above were performed with ip administration, whereas the clinical route of treatment of neonatal seizures is typically intravenous (iv).\textsuperscript{5} Preliminary experiments in P11 rat pups showed that iv administration via the tail veins is easily possible before asphyxia. However, immediately after asphyxia, the tail veins were constricted, most likely as a consequence of circulatory centralization, so that iv injection was successful in only ~20% of the pups. We therefore decided to skip the iv route in the present study.

### 3.3 Drug levels in plasma and brain

When phenobarbital (15 or 30 mg/kg ip) was administered 15 minutes before onset of asphyxia and plasma and brain drug levels were determined 10 minutes after termination of asphyxia, that is, shortly after the postasphyxic seizures, brain levels of phenobarbital were only moderately lower than those determined in plasma, with average brain:plasma ratios of 0.71 (15 mg/kg) and 0.77 (30 mg/kg), respectively (Figure 4). Combined treatment with bumetanide did not significantly affect plasma or brain levels of phenobarbital (15 mg/kg) or its plasma:brain ratio (Figure 4). When phenobarbital (30 mg/kg) was administered immediately after asphyxia and plasma and brain levels were determined 10 minutes later, brain levels and the brain:plasma ratio of phenobarbital were significantly lower compared to the values determined 55 minutes after drug administration (Figure 4B,C). This can be readily explained by the relatively slow brain penetration of this drug, which reaches maximal brain levels only at ≥2 hours after iv administration in rats.\textsuperscript{31}

In contrast to phenobarbital, as reported previously for adult rodents,\textsuperscript{24,32,33} bumetanide only poorly penetrated into the brain, resulting in an average brain:plasma ratio of only 0.036, when bumetanide (0.3 mg/kg) was injected 15 minutes before asphyxia (Figure 4C). Significantly higher brain levels were determined when the same dose of bumetanide was injected immediately after asphyxia (ie, about 10 minutes before determining plasma and brain levels; Figure 4B), thus indicating a very rapid (but incomplete) penetration of this drug into the brain. Phenobarbital did not alter the plasma or brain levels of bumetanide (Figure 4). Thus, as shown previously,\textsuperscript{14} the blood-brain barrier (BBB) of neonatal rats is not more penetrable by bumetanide than the BBB of adults, so that brain bumetanide levels (~0.01-0.03 µg/mL = 0.028-0.084 µM) were far below those needed to inhibit NKCC1, particularly when considering the extensive brain tissue binding of bumetanide (cf Brundt et al\textsuperscript{15}).

It is also important to note that in rodents, bumetanide is much more rapidly eliminated than phenobarbital. The average elimination half-life of bumetanide in adult rats is only ~10 minutes\textsuperscript{24} compared to 9-20 hours for phenobarbital\textsuperscript{24}; the interdrug difference in elimination half-life may be even higher in neonatal rats.

Midazolam (1 mg/kg) achieved about the same plasma and brain concentrations, irrespective of whether the drug was administered before or after asphyxia (Figure 4). Brain:plasma ratio was about 2.2-2.4, indicating brain accumulation of this...
lipophilic drug. At the lower dose of midazolam (0.3 mg/kg), administered after asphyxia, plasma and brain levels were about one-third of those determined at 1 mg/kg, but the brain:plasma ratio was the same (Figure 4).

4 | DISCUSSION

The present study illustrates the antiseizure efficacy of clinically used ASDs in a recently described novel rat model of birth asphyxia, whereas the NKCC1 inhibitor bumetanide is ineffective. To our knowledge, this is the first rodent model of postasphyxic neonatal seizures that allows testing of drugs after asphyxia, because, as in human neonates, seizures occur during establishment of normocapnic conditions (see Introduction). As shown here, administration of midazolam after asphyxia blocked seizures in about 50% of the rat pups, whereas phenobarbital was not effective, most likely as a consequence of its slow brain penetration. When high doses of phenobarbital or midazolam were administered shortly before asphyxia, both drugs blocked postasphyxic convulsive seizures, whereas nonconvulsive seizures were resistent. Bumetanide was not capable of potentiating the effect of phenobarbital, independently of whether it was administered before or after asphyxia. The present translational data obtained with the novel rat model of birth asphyxia indicate that this model is a useful tool to evaluate novel treatments for neonatal seizures.

As discussed in detail recently, the present model of asphyxia-induced neonatal seizures in P11 rat pups parallels human birth asphyxia but differs in several important aspects from the pure-hypoxia models that are widely used in neonatal research. As pointed out in the Introduction, in human neonates, the most common cause of postnatal seizures is prolonged perinatal asphyxia, exposing the fetus or newborn to hypoxia and hypercapnia with significant acidosis, which suppresses neuronal activity during asphyxia. This is also observed in the present model as exemplified by the decreased EEG amplitude during asphyxia. As in human neonates, seizures are observed during recovery from asphyxia, and these seizures are paralleled by a rise in blood and brain pH. The postasphyxic seizures observed in the present model cover the whole spectrum of neonatal seizures that occur in human newborns. Thus, the present model closes an important gap (see, eg, Lombroso) between the laboratory and the clinic. In line with this conclusion, the pharmacology of the postasphyxic seizures in P11 rat pups seems to be more translationally relevant than previous drug studies in other models of neonatal seizures, in which the seizures were induced by hypoxia or the excitotoxotoxic convulsant kainate.

The negative outcome of the present experiment with bumetanide (0.3 mg/kg ip) as adjunct to phenobarbital (15 or 30 mg/kg ip) for treatment of postasphyxic neonatal seizures is in line with the negative outcome of the European multicenter NEMO trial reported by Pressler et al. Thus, the present asphyxia model correctly predicts the failure of bumetanide to increase the antiseizure efficacy of phenobarbital in human neonates. This is in contrast to the study performed by Cleary et al in a noninvasive rat hypoxia model, in which bumetanide (administered before hypoxia) potentiated the antiseizure efficacy of phenobarbital with exactly the same doses and pretreatment times that have been used here. Interestingly, in a mouse model of ischemia-induced neonatal seizures in mice, bumetanide (0.1-0.2 mg/kg) also failed to potentiate the action of phenobarbital (25 mg/kg) at P7 and P12, and significantly blunted the effect of phenobarbital at P10. Thus, when using an etiologically relevant rodent model of neonatal seizures, bumetanide, administered at clinically relevant doses, is not an effective adjunct of phenobarbital.

This is not surprising, because bumetanide only poorly penetrates into the brain and is highly bound to brain lipids and proteins, so that it does not reach NKCC1-inhibitory brain levels at clinically relevant doses. Thus, it is difficult to explain by which mechanism(s) clinically used doses of bumetanide (0.1-0.5 mg/kg ip) potentiated the antiseizure effect of phenobarbital or suppressed seizures when administered alone in hypoxia models of neonatal seizures. Effects of bumetanide on apically expressed NKCC1 in the BBB, off-target effects (not mediated by NKCC1), and systemic effects of bumetanide have been discussed in this context. At a much higher dose (10 mg/kg ip), bumetanide enhanced the antiseizure effect of phenobarbital in an invasive neonatal cerebral hypoxia-ischemia rat model, but this effect was lost at 2.5 mg/kg bumetanide. At 10 mg/kg, unbound brain levels of bumetanide reach the concentration range (0.1-0.3 µM) needed to inhibit NKCC1. It will be interesting to see whether the more BBB-permeable bumetanide prodrugs examined in our previous work are more efficient than the parent compound in the present model.

In contrast to the inability of bumetanide to potentiate the antiseizure effect of phenobarbital (15 mg/kg) in the present model, the higher, still clinically relevant dose of phenobarbital (30 mg/kg) was quite effective to reduce seizure incidence when applied before, but not after, the asphyxia exposure. Similarly, the potent benzodiazepine midazolam suppressed the seizures, which is in line with its use as a second-line ASD for neonatal seizures. Interestingly, midazolam was effective in suppressing the seizures when injected either before or after asphyxia (before seizure onset), thus substantiating its rapid brain penetration. It may be argued that the effective dose (1 mg/kg) of midazolam used here was considerably higher than the average dose (0.15-0.3 mg/kg) used clinically. However, as a result of different administration routes (ip here and iv clinically) and species differences.
in drug elimination and body surface area, the average plasma levels 10 minutes after ip administration of midazolam (1 mg/kg) in rat pups (~0.18 µg/mL) were in the range (~0.14-0.2 µg/mL) determined 10 minutes after iv administration of 0.1-0.2 mg/kg in pediatric patients. At a lower, clinically relevant dose of midazolam (0.3 mg/kg), which was administered after asphyxia, seizures were only prevented in ~30% of the rat pups. However, the severe generalized convulsive (stage III-V) seizures were completely prevented by this dose of midazolam.

Despite the efficacy of midazolam and phenobarbital to block convulsive neonatal seizures, both drugs were ineffective to suppress nonconvulsive seizures, that is, the most frequent type of neonatal seizures in humans. Furthermore, both drugs may induce apoptotic neuronal death in specific regions of the immature brain and increase neonatal seizure-associated neuronal injury, so novel treatments for neonatal seizures are urgently needed. The present model of asphyxia-induced neonatal seizures may help to identify such novel therapies.

Some of the properties of the present model of birth asphyxia have immediate implications for the technical design of pharmacological experiments. The onset of epileptiform activity is fast, starting around 2 minutes after the end of asphyxia. Although this is a clear advantage over noninvasive hypoxia-only models, in which seizures occur during hypoxia, the short latency between asphyxia and onset of seizures in the present model complicates drug testing for pharmacokinetic reasons. This limits the range of ASDs that can be tested for antiseizure efficacy after asphyxia to drugs such as midazolam, which penetrates extremely fast into the brain, whereas drugs such as phenobarbital do not reach sufficiently high levels at their brain targets within the time frame necessary. This is illustrated by the different efficacy of high-dose phenobarbital administered before versus after asphyxia in the present study. Bumetanide did not potentiate phenobarbital when being administered as adjunct to phenobarbital after asphyxia. A study design with drug administration after asphyxia would better represent the clinical treatment of human birth asphyxia.

Interestingly, in the experiments of Kang et al, in which phenobarbital (25 mg/kg ip) was given 1 hour after onset of permanent unilateral carotid-ligation to produce acute ischemic seizures on P7, P10, and P12 CD1 mice, phenobarbital was effective as an antiseizure agent at P10 and P12, but bumetanide as an adjunct failed to improve the efficacy of phenobarbital. Thus, the outcome of our study design with administration of phenobarbital and bumetanide before and after asphyxia is similar to the results of Kang et al with administration of these drugs after onset of an ischemic insult.

In human neonates, ASDs are typically administered iv, whereas we used ip administration here, which has pharmacokinetic limitations such as lower bioavailability and slower onset of pharmacological effects compared to the iv route. As described in Results, we tried to inject drugs iv before and after asphyxia in rat pups, but the yield of successful iv drug injections after asphyxia was too low to allow using this route routinely in large groups of pups. This was a result of circulatory centralization after asphyxia, leading to tail vein constriction, which is inherent in all valid noninvasive models of asphyxia. Chronic implantation of iv catheters before onset of asphyxia and some of the iv injection techniques that have been described previously in neonatal rodents are feasible alternatives for future experiments, although all these techniques are exacting procedures.

Increased neuronal NKCC1 expression has been implicated in neonatal seizures in humans (although data supporting this hypothesis are missing), but the role of NKCC1 upregulation, if any, in the present model is not yet known. Cleary et al reported that the expression of NKCC1 protein transiently increased in cortex and hippocampus after hypoxic seizures in P10 rat pups. In apparent contrast, no significant changes were detected in NKCC1 expression in the mouse model of ischemia-induced neonatal seizures used by Kang et al. We plan to quantify NKCC1 brain expression in our model as well, using novel specific antibodies together with proper NKCC1 knockout controls for the visualization of endogenous NKCC1 in distinct cell types and their subcellular compartments. In this respect, it is important to note that (1) most of the NKCC1 in brain tissue is expressed in glial cells, oligodendrocytes, astroglia, and microglia but not in neurons; and (2) the lack of specific NKCC1 antibodies has thus far complicated the interpretation of immunohistochemical studies on the subcellular distribution of NKCC1. These technical issues seem to explain most of the discrepancies in NKCC1 expression in the pertinent literature.

In conclusion, as outlined in detail recently, the non-invasive rat model used here is the first physiologically-valid rodent model of birth asphyxia with neonatal seizures triggered after the insult. The present pharmacological data indicate that this model is a useful tool to evaluate current as well as novel treatments for neonatal seizures. Furthermore, our model may be used to study the detrimental long-term consequences of neonatal asphyxia and seizures and whether it is possible to prevent or minimize such consequences by pharmacological intervention after asphyxia.

**ACKNOWLEDGMENTS**

We thank Edith Kaczmarek and Martina Gramer for skillful technical assistance. The study was supported in part by a grant from the Deutsche Forschungsgemeinschaft (Lo 274/15-1). The open access publication was supported by the Deutsche Forschungsgemeinschaft and University of Veterinary Medicine Hannover, Foundation, within the funding program Open Access Publishing enabled and organized by Projekt DEAL.
CONFLICT OF INTEREST

None of the other authors has any conflict of interest to disclose.

ETHICAL PUBLICATION STATEMENT

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Marie Johne https://orcid.org/0000-0002-0490-2648
Philip Hampel https://orcid.org/0000-0002-5391-555X
Björn Gailus https://orcid.org/0000-0002-1980-7133
Tommi Ala-Kurikka https://orcid.org/0000-0003-2452-9032
Wolfgang Löscher https://orcid.org/0000-0002-9648-8973

REFERENCES

1. Pressler R, Cilio MR, Mizrahi EM, Moshé SL, Nunes ML, Plouin P, et al. The ILAE classification of seizures & the epilepsies: modification for seizures in the neonate. Proposal from the ILAE task force on neonatal seizures. Epilepsia. In press.
2. Silverstein FS, Jensen FE. Neonatal seizures. Ann Neurol. 2007;62:112–20.
3. WHO. Guidelines on Neonatal Seizures. Geneva, Switzerland: World Health Organization; 2011.
4. Ikonomidou C. Triggers of apoptosis in the immature brain. Brain Dev. 2009;31:488–92.
5. Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB. Pharmacotherapy for neonatal seizures: current knowledge and future perspectives. Drugs. 2016;76:647–61.
6. Pressler RM, Mangum B. Newly emerging therapies for neonatal seizures. Semin Fetal Neonatal Med. 2013;18:216–23.
7. Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53(Suppl. 8):12–25.
8. Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15:637–54.
9. Puskarjov M, Kahle KT, Ruusuvuori E, Kaila K. Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. Epilepsia. 2014;55:806–18.
10. Kahle KT, Staley KJ. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures. Neurosurg Focus. 2008;25:1–8.
11. Ben AY. NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders. Trends Neurosci. 2017;40:536–54.
12. Khazipov R, Zaynutdinova D, Ogievetsky E, Valeeva G, Mitrukhina O, Manent J-B, et al. Atlas of the postnatal rat brain in stereotaxic coordinates. Front Neuroanat. 2015;9:161.
13. Klein S, Bankstahl M, Grauer M, Hausknecht M, Löscher W. Low doses of ethanol markedly potentiate the anticonvulsant effect of diazepam in a mouse model of difficult-to-treat focal seizures. Epilepsy Res. 2014;108:1719–27.
14. Brandt C, Nozadze M, Heuchert N, Rattka M, Löscher W. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci. 2010;30:8602–12.
15. Barnard GA. Significance tests for 2 × 2 tables. Biometrika. 1947;34:123–38.
16. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 × 2 tables. Stat Med. 2009;28:1159–75.
17. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
18. Lüscher W, Frey H-H. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia. 1984;25:346–52.
19. Monaco F, Sechi G. The brain distribution of old and new antiepileptic drugs. Epilepsy Res Suppl. 1991;3:57–65.
20. Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15:637–54.
21. Barnard GA. Significance tests for 2 × 2 tables. Biometrika. 1947;34:123–38.
22. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 × 2 tables. Stat Med. 2009;28:1159–75.
23. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
24. Lüscher W, Frey H-H. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia. 1984;25:346–52.
25. Monaco F, Sechi G. The brain distribution of old and new antiepileptic drugs. Epilepsy Res Suppl. 1991;3:57–65.
26. Griffin CE III, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13:214–23.
27. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32:281–94.
28. Claasen T, Kaila K. The brain distribution of old and new antiepileptic drugs. Epilepsy Res Suppl. 1991;3:57–65.
prolonged drug administration in rat models of epilepsy. Epilepsia. 2007;48:1245–58.
35. Sun H, Juul HM, Jensen FE. Models of hypoxia and ischemia-induced seizures. J Neurosci Methods. 2016;260:252–60.
36. Helmy MM, Tolner EA, Vanhatalo S, Voipio J, Kaila K. Brain alkalosis causes birth asphyxia seizures, suggesting therapeutic strategy. Ann Neurol. 2011;69:493–500.
37. Lombroso CT. Neonatal seizures: gaps between the laboratory and the clinic. Epilepsia. 2007;48(Suppl. 2):83–106.
38. Dzhala VI, Talos DM, Sdrulla DA, Brumbach AC, Mathews GC, Benke TA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005;11:1205–13.
39. Liu Y, Shangguan Y, Barks JD, Silverstein FS. Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model. Pediatr Res. 2012;71:559–65.
40. Wang S, Zhang XQ, Song CG, Xiao T, Zhao M, Zhu G, et al. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures. Neuroscience. 2015;286:203–15.
41. Kang SK, Markowitz GI, Kim ST, Johnston MV, Kadam SD. Age- and sex-dependent susceptibility to phenobarbital-resistant neonatal seizures: role of chloride co-transporters. Front Cell Neurosci. 2015;9:173.
42. Töllner K, Brandt C, Töpfer M, Brunhofer G, Erker T, Gabriel M, et al. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol. 2014;75:550–62.
43. Sankar JM, Agarwal R, Deorari A, Paul VK. Age of neonatal seizures. Indian J Pediatr. 2010;77:1129–35.
44. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.
45. Rey E, Delaunay L, Pons G, Murat I, Richard MO, Saint-Maurice C, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol. 1991;41:355–7.
46. Tolia V, Brennan S, Aravind MK, Kauffman RE. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr. 1991;119:467–71.
47. Torolira D, Suchomelova L, Wasterlain CG, Niquet J. Phenobarbital and midazolam increase neonatal seizure-associated neuronal injury. Ann Neurol. 2017;82:115–20.
48. Soul JS. Acute symptomatic seizures in term neonates: etiologies and treatments. Semin Fetal Neonatal Med. 2018;23:183–90.
49. Anderson NF, Delorme EJ, Woodruff MF, Simpson DC. An improved technique for intravenous injection of new-born rats and mice. Nature. 1959;184(Suppl 25):1952–3.
50. Kienstra KA, Freysdottir D, Gonzales NM, Hirschi KK. Murine neonatal intravascular injections: modeling newborn disease. J Am Assoc Lab Anim Sci. 2007;46:50–4.
51. Chen B, Yoon JS, Hu B, Basta M. High-dose intravenous immunoglobulin exerts neuroprotective effect in the rat model of neonatal asphyxia. Pediatr Res. 2014;75:612–7.
52. Gombash Lampe SE, Kaspar BK, Foust KD. Intravenous injections in neonatal mice. J Vis Exp. 2014;(93):e52037.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.